Congenital Heart Surgeons' Society
CHSS Home CHSS Home Past & Future Meetings Past & Future Meetings

Back to 2023 Abstracts


Promising Outcomes: Supporting Fontan Patients With Systemic Ventricular Assist Device Therapy
Spencer J. Hogue, BS, Kevin Kulshrestha, MD, MBE, Angela Lorts, MD, MBA, Tanya Perry, DO, Katrina Fields, RN, Chet Villa, MD, David G. Lehenbauer, MD, David L. S. Morales, MD
Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Objectives: Single ventricular assist devices (SVAD) have emerged as a promising therapy for Fontan patients with failing circulation. Therefore, we analyzed our institution's Fontan SVAD experience to highlight outcomes in this cohort.
Methods: All Fontan patients that underwent SVAD implantation at our institution from 2016-2023 were retrospectively reviewed.
Results: Twelve patients were included, predominantly consisting of patients with a HLHS diagnosis (67%, n=8). All patients were palliated with extracardiac conduit (58%, n=7) or lateral tunnel (42%, n=5) Fontan circulations. SVAD implantation occurred at a median of 9.5 [IQR:2.3-23.3] years post-Fontan. Temporary SVAD exchange to durable support occurred in three (25%) patients. All patients except one (n=11) were ensured to have a fenestration. A majority of SVADs were purposed for bridging patients to transplant candidacy (58%, n=7). The median duration of SVAD support and hospital length of stay were 104 [IQR:39-546] and 37 [IQR:24-137] days, respectively. Two (17%) patients remain supported and two (17%) in-hospital mortalities occurred at 11 and 52 days post-SVAD; these patients were ≥37 years old. Eight (67%) patients received a heart (n=7) or en-bloc heart-liver (n=1) transplant. The median follow-up was 2.6 [IQR:1.6-3.7] years. For the overall cohort, the in-hospital, one-, and three-year survivals were 83%. (Table)
Conclusions: Though Fontan failure remains a challenging physiologic state, this series demonstrates promising results, supporting that these patients can be effectively managed with SVAD therapy.

Table. Characteristics and outcomes of Fontan patients receiving SVAD support.
Demographics
Male sex9 (75%)
White race8 (67%)
Age (years)23.8 [IQR 13.3-30.9]
Weight (kg)69.9 [IQR 39.7-73.3]
Primary Cardiac Diagnoses
Hypoplastic Left Heart Syndrome8 (67%)
Tricuspid Atresia2 (17%)
Double Outlet Left Ventricle1 (8%)
Double Inlet Left Ventricle1 (8%)
SVAD Implant
SVAD Support Duration (days)104 [IQR 39-546]
Performed with no CPB (EXCORs)2 (17%)
Durable SVAD Types
HeartMate 39 (75%)
Berlin Heart EXCOR2 (17%)
Heartware1 (8%)
Temporary SVAD Types
Median Support Duration (days)3.5 [IQR 3.0-5.5]
Centrimag2 (17%)
Impella1 (8%)
SVAD Purpose
Bridge to Transplant4 (33%)
Bridge to Transplant Candidacy7 (58%)
Bridge to Recovery1 (8%)
Concomitant Procedures
Fontan Conduit Fenestration6 (50%)
Fontan Revision2 (17%)
Aortic Valve Repair1 (8%)
Mitral Valve Repair1 (8%)
Carotid Artery Repair1 (8%)
Damus-Kaye-Stansel Takedown1 (8%)
In-hospital Re-interventions3 Patients (35%)
Mediastinal Hematoma Evacuation2 (17%)
SVAD Repositioning2 (17%)
Oxygenator Placement1 (8%)


Back to 2023 Abstracts